Rani Therapeutics (RANI) Expected to Announce Earnings on Wednesday

Rani Therapeutics (NASDAQ:RANI) is expected to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect Rani Therapeutics to post earnings of ($0.24) per share for the quarter.

Rani Therapeutics Stock Up 3.4 %

Shares of Rani Therapeutics stock opened at $1.51 on Monday. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 2.34. The business’s 50 day simple moving average is $1.49 and its 200-day simple moving average is $1.93. The stock has a market capitalization of $86.51 million, a price-to-earnings ratio of -1.42 and a beta of 0.14. Rani Therapeutics has a twelve month low of $1.24 and a twelve month high of $8.75.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a research report on Friday, February 7th. Canaccord Genuity Group restated a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a research report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Rani Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.